Steven Gillis - Pulmatrix Director
PULM Stock | USD 1.75 0.13 8.02% |
Director
Dr. Steven H. Gillis Ph.D., is Independent Director of the Company. Dr. Gillis was previously a director of Pulmatrix Operating from October 2009 until the date of the Merger. Since 2005, Dr. Gillis was a Managing Director at ARCH Venture Partners, a VC firm. From 1994 to 2005, Dr. Gillis served as Chief Executive Officer and chairman of the board of directors of Corixa Corporationrationration, which he cofounded in October 1994. Previously, Dr. Gillis served as a director, head of research and development, chief scientific officer and acting chief executive officer of Immunex Corporationrationration, which he cofounded. As a former director and chairman of Trubion Pharmaceuticals, Inc., Dr. Gillis led its acquisition by Emergent BioSolutions in the fall of 2010. Dr. Gillis currently serves as a director of Shire plc, Accelerator Corporationrationration, Oncofactor Corporationration and VBI Vaccines and serves as director and chairman of VentiRX Pharmaceuticals, Inc., Theraclone Sciences, Inc., Lycera Corporationration, Faraday Pharmaceuticals, Inc., Homology Medicines, Inc. and PhaseRx, Inc since 2015.
Age | 65 |
Tenure | 9 years |
Address | 99 Hayden Avenue, Lexington, MA, United States, 02421 |
Phone | 781 357 2333 |
Web | https://www.pulmatrix.com |
Latest Insider Transactions
Gillis received his B.A. in Biology and English from Williams College and his Ph.D. in Biological Science from Dartmouth College. We believe that Dr. Gillis’s experience in the VC industry, particularly with biotechnology and pharmaceutical companies, qualifies him to serve as a member of the Board.Steven Gillis Latest Insider Activity
Tracking and analyzing the buying and selling activities of Steven Gillis against Pulmatrix stock is an integral part of due diligence when investing in Pulmatrix. Steven Gillis insider activity provides valuable insight into whether Pulmatrix is net buyers or sellers over its current business cycle. Note, Pulmatrix insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pulmatrix'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Steven Gillis over a year ago Acquisition by Steven Gillis of 75000 shares of VBI Vaccines subject to Rule 16b-3 |
Pulmatrix Management Efficiency
The company has return on total asset (ROA) of (0.2529) % which means that it has lost $0.2529 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5918) %, meaning that it created substantial loss on money invested by shareholders. Pulmatrix's management efficiency ratios could be used to measure how well Pulmatrix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to drop to -0.5. In addition to that, Return On Assets is likely to drop to -0.43. At this time, Pulmatrix's Other Current Assets are very stable compared to the past year. As of the 28th of March 2024, Net Tangible Assets is likely to grow to about 37.6 M, while Non Current Assets Total are likely to drop about 3.1 M.Similar Executives
Showing other executives | DIRECTOR Age | ||
Mala Anand | Agilent Technologies | 53 | |
David Milligan | Madrigal Pharmaceuticals | 77 | |
Charles McDermott | Equillium | 45 | |
Americo Romano | 23Andme Holding Co | 58 | |
Willard Dere | Seres Therapeutics | 64 | |
Heidi Kunz | Agilent Technologies | 66 | |
George Scangos | Agilent Technologies | 72 | |
Staffan Gavel | 23Andme Holding Co | 67 | |
Helena Herlogsson | 23Andme Holding Co | N/A | |
Meryl Zausner | Seres Therapeutics | 61 | |
Werner Cautreels | Seres Therapeutics | N/A | |
Bala Manian | Equillium | 72 | |
Mark Pruzanski | Equillium | 50 | |
Daniel Podolsky | Agilent Technologies | 67 | |
Richard Kender | Seres Therapeutics | 62 | |
Bruce Kovner | Madrigal Pharmaceuticals | 69 | |
Kenneth Bate | Madrigal Pharmaceuticals | 67 | |
David Berry | Seres Therapeutics | 37 | |
Richard Levy | Madrigal Pharmaceuticals | 60 | |
Lorence Kim | Seres Therapeutics | 43 | |
Giuseppe Lettieri | 23Andme Holding Co | 33 |
Management Performance
Return On Equity | -0.59 | ||||
Return On Asset | -0.25 |
Pulmatrix Leadership Team
Elected by the shareholders, the Pulmatrix's board of directors comprises two types of representatives: Pulmatrix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pulmatrix. The board's role is to monitor Pulmatrix's management team and ensure that shareholders' interests are well served. Pulmatrix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pulmatrix's outside directors are responsible for providing unbiased perspectives on the board's policies.
MBA CMA, Interim Officer | ||
Terrance McGuire, Director | ||
Matthew Sherman, Director | ||
David Hava, Chief Scientific Officer | ||
Alexander Klibanov, Founder | ||
Akihisa Akao, Director | ||
James Roach, Chief Medical Officer | ||
Michael Higgins, Director | ||
Steven Gillis, Director | ||
Jean Sung, Vice President - Pharmaceutical Development | ||
William Duke, CFO, Principal Financial Officer & Principal Accounting Officer | ||
Robert Clarke, CEO and President and Director | ||
Scott Rocklage, Director | ||
Kurt Graves, Director | ||
Richard Conley, Independent Director | ||
Mark Iwicki, Chairman of the Board | ||
Amit Munshi, Director | ||
Gregory French, Independent Director | ||
Margaret MD, Chief Officer | ||
Ted Raad, CEO, Director | ||
David JD, Advisor | ||
Aidan Curran, VP Affairs | ||
Teofilo MBA, CEO President | ||
Teofilo Raad, CEO, Director |
Pulmatrix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pulmatrix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pulmatrix using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Pulmatrix Stock analysis
When running Pulmatrix's price analysis, check to measure Pulmatrix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulmatrix is operating at the current time. Most of Pulmatrix's value examination focuses on studying past and present price action to predict the probability of Pulmatrix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulmatrix's price. Additionally, you may evaluate how the addition of Pulmatrix to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
CEOs Directory Screen CEOs from public companies around the world | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is Pulmatrix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.44) | Revenue Per Share 1.865 | Quarterly Revenue Growth (0.06) | Return On Assets (0.25) | Return On Equity (0.59) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.